361 related articles for article (PubMed ID: 26601869)
1. Mucosal Melanoma: Epidemiology, Biology and Treatment.
Spencer KR; Mehnert JM
Cancer Treat Res; 2016; 167():295-320. PubMed ID: 26601869
[TBL] [Abstract][Full Text] [Related]
2. Management of Acral and Mucosal Melanoma: Medical Oncology Perspective.
Jung S; Johnson DB
Oncologist; 2022 Aug; 27(8):703-710. PubMed ID: 35640549
[TBL] [Abstract][Full Text] [Related]
3. Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment.
Sergi MC; Filoni E; Triggiano G; Cazzato G; Internò V; Porta C; Tucci M
Curr Oncol Rep; 2023 Nov; 25(11):1247-1258. PubMed ID: 37773078
[TBL] [Abstract][Full Text] [Related]
4. Mucosal melanomas.
Tomicic J; Wanebo HJ
Surg Clin North Am; 2003 Apr; 83(2):237-52. PubMed ID: 12744608
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis.
Bishop KD; Olszewski AJ
Int J Cancer; 2014 Jun; 134(12):2961-71. PubMed ID: 24272143
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy for malignant melanoma].
Zaremba A; Zimmer L; Griewank KG; Ugurel S; Roesch A; Schadendorf D; Livingstone E
Internist (Berl); 2020 Jul; 61(7):669-675. PubMed ID: 32462249
[TBL] [Abstract][Full Text] [Related]
8. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.
Papaspyrou G; Garbe C; Schadendorf D; Werner JA; Hauschild A; Egberts F
Melanoma Res; 2011 Dec; 21(6):475-82. PubMed ID: 21897303
[TBL] [Abstract][Full Text] [Related]
9. Acral melanoma foot lesions. Part 1: epidemiology, aetiology, and molecular pathology.
Desai A; Ugorji R; Khachemoune A
Clin Exp Dermatol; 2017 Dec; 42(8):845-848. PubMed ID: 28940724
[TBL] [Abstract][Full Text] [Related]
10. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
11. Multimodality Imaging and Genetics of Primary Mucosal Melanomas and Response to Treatment.
Saleh M; Javadi S; Elsherif S; Patnana M; Sagebiel TL; Torres-Cabala C; Mattei J; Bhosale P; Faria SC
Radiographics; 2021; 41(7):1954-1972. PubMed ID: 34678102
[TBL] [Abstract][Full Text] [Related]
12. Primary mucosal melanomas: a comprehensive review.
Mihajlovic M; Vlajkovic S; Jovanovic P; Stefanovic V
Int J Clin Exp Pathol; 2012; 5(8):739-53. PubMed ID: 23071856
[TBL] [Abstract][Full Text] [Related]
13. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure.
Handolias D; Salemi R; Murray W; Tan A; Liu W; Viros A; Dobrovic A; Kelly J; McArthur GA
Pigment Cell Melanoma Res; 2010 Apr; 23(2):210-5. PubMed ID: 20088873
[TBL] [Abstract][Full Text] [Related]
14. Mucosal melanoma: a clinically and biologically unique disease entity.
Carvajal RD; Spencer SA; Lydiatt W
J Natl Compr Canc Netw; 2012 Mar; 10(3):345-56. PubMed ID: 22393195
[TBL] [Abstract][Full Text] [Related]
15. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
16. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
Rajkumar S; Watson IR
Br J Cancer; 2016 Jul; 115(2):145-55. PubMed ID: 27336610
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.
Mao L; Qi Z; Zhang L; Guo J; Si L
Front Immunol; 2021; 12():680407. PubMed ID: 34149718
[TBL] [Abstract][Full Text] [Related]
19. Update on primary mucosal melanoma.
Tacastacas JD; Bray J; Cohen YK; Arbesman J; Kim J; Koon HB; Honda K; Cooper KD; Gerstenblith MR
J Am Acad Dermatol; 2014 Aug; 71(2):366-75. PubMed ID: 24815565
[TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
